Last edition
News about "DARZALEX FASPRO"
FDA Approves DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma
The US FDA has approved DARZALEX Faspro as the first treatment for adult patients with High-Risk Smoldering Multiple Myeloma (HR-SMM), marking a key milestone in addressing this early stage of the disease.
DARZALEX Faspro | 11/11/2025 | By Dineshwori
European Commission Approves DARZALEX Faspro for Adults with Smouldering Multiple Myeloma
Halozyme Therapeutics has announced European Commission approval for DARZALEX Faspro, co-formulated with ENHANZE, as a monotherapy for high-risk smouldering multiple myeloma in adults, marking a shift from passive monitoring to early intervention.
DARZALEX Faspro | 24/07/2025 | By Mrinmoy Dey | 132
Johnson & Johnson Submits sBLA to FDA for Approval of DARZALEX FASPRO-Based Quadruplet Regimen
The CEPHEUS study evaluated the efficacy and safety of D-VRd compared to bortezomib, lenalidomide and dexamethasone (VRd) for NDMM patients for whom ASCT was not planned as initial therapy.
DARZALEX FASPRO | 01/10/2024 | By Aishwarya | 240
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy